CoreWeave funding capex under colocation contracts
Company: Core Scientific
The claim, verbatim
CoreWeave funds a portion of Core Scientific's capital expenditures under previously announced contractual agreements, covering $90.3 million of Q2 2025 capex.
Source (primary)
core-scientific 8-K exhibit (q22025corescientificinc-ea.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-10-07)Live source ↗
Quote: “Capital expenditures were $121.3 million, with $90.3 million funded by CoreWeave under the previously announced contractual agreements.”
How we checked this
Checked on October 9, 2026. The cited source supports every part of this claim.
The release states Q2 2025 capital expenditures were $121.3 million, with $90.3 million funded by CoreWeave under previously announced contractual agreements.
Confirmed in the source:
- CoreWeave funded a portion of Core Scientific's capital expenditures under previously announced contractual agreements
- CoreWeave funded $90.3 million of Core Scientific's Q2 2025 capital expenditures, out of a total of $121.3 million
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000162828025039283/q22025corescientificinc-ea.htm) in full (28,889 characters, retrieved October 7, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (q22025corescientificinc-ea.htm)
Quote: “Capital expenditures were $121.3 million, with $90.3 million funded by CoreWeave under the previously announced contractual agreements.”